-+ 0.00%
-+ 0.00%
-+ 0.00%

Solid Biosciences Doses Five Participants in Friedreich’s Ataxia Gene Therapy Trial

PUBT·10/26/2026 12:11:35
Listen to the news
Solid Biosciences Doses Five Participants in Friedreich’s Ataxia Gene Therapy Trial
  • Solid Biosciences received European Commission orphan designation for SGT-212, its investigational gene therapy for Friedreich’s ataxia.
  • Five participants were dosed in Phase 1b FALCON, with no treatment-related serious adverse events as of October 5, 2026.
  • Initial clinical data from FALCON are expected in the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260800PRIMZONEFULLFEED9852928) on October 26, 2026, and is solely responsible for the information contained therein.